BD近日报告称，其第二季度财政收入上涨了42%，主要由对CR Bard（巴德）的收购导致。BD称，在可比的、货币中立的基础上，第二季度收入增长了5%。

截至3月31日的三个月内，BD公布的营收为42亿2000万美元，较上年同期的29亿7000万美元高，超过分析师平均预期的41亿2000万美元。

BD的医疗部门从一年前的18亿2000万美元增长了20%，今年已达21亿7000万美元。BD生命科学公司的收入从上年同期的9亿8200万美元增长了12%，达到11亿美元。在该段内，预分析系统收入从3亿6300万美元上升5%，至3亿8100万美元，而诊断系统收入从3亿5000万美元上升17%美元至4亿1000万美元，生物科学收入从2亿6900万美元增加14%美元至3亿700万美元。

美国生命科学领域的增长归因于诊断系统和生物科学的强劲增长，而在预分析系统中的收入受到其在本季度解决的一条生产线中的生产问题的负面影响。美国生命科学领域的增长也得益于强流感期，诊断系统等流感相关收入的增加。

BD董事长兼首席执行官VincentForlenza在一份声明中说：“本季度的业绩是我们120年历史上的一个重要里程碑，我们欢迎CR Bard来到BD。”BD在2017年底完成了对巴德240亿美元的收购，根据美国联邦贸易委员会的要求，这两家公司剥离了部分医疗器械产品线。

诊断一直是BD的重要部门之一。BD目前大约安装了30000个Veritor免疫分析系统，公司的执行副总裁兼生命科学部总裁Alberto Mas说。Mas指出，该公司正在通过其Veritor诊断系统占据更多的手动检测市场。“我们最近推出了我们Veritor的连接版本，这使我们能够更好地渗入零售环节，”他补充说。BD也在尝试提供更广泛的菜单，且正在为系统进行额外的测试，但现在提供更多细节的过程中还太早。

该公司美国业务的收入从一年前的16亿3000万美元增长了43%，达到23亿3000万美元，而国际市场的收入从第二季度的13亿4000万美元上涨了41%，达到19亿美元。

该公司称，美国以外的收入在可比、货币中性的基础上增长了约8%，反映出了医疗、生命科学和介入领域的强劲表现。

BD的季度净亏损为1200万美元，即每股0.19美元，而一年前的净收入为3亿4400万美元，即每股1.58美元。最近刚结束的季度，调整后每股收益为2.65美元，超出了华尔街2.63美元的预期。

BD第二季度的R&D费用从去年的1亿8700万美元增长了23%，达到2亿3000美元，其SG&A成本从7亿2400万美元上涨46%，升至10亿6000万美元。销售产品的成本也比去年增加了70%，从15亿4000万美元增加到26亿2000万美元，而与收购和其他重组相关的成本上升了37%，从7600万美元上升到1亿400万美元。

该公司增加了其2018财年全年收入和调整后每股收益的指导。该公司的预计收入增长在31%到31.5%之间，而之前的预期增长是30%到31%。在可比较的、货币中性的基础上，该公司将其收入导向提高到5%到5.5%的增长率，这是他们之前指导范围的较高部分。

BD股价在纽约证券交易所早盘交易中下跌3%，至223.10美元。

Becton Dickinson Fiscal Q2 Revenues Up 42 Percent Reflecting Bard Acquisition

Becton Dickinson reported today that its fiscal second quarter revenues rose 42 percent year over year, reflecting the acquisition of CR Bard. On a comparable, currency-neutral basis, Q2 revenues grew 5 percent, BD said.

For the three months ended March 31, BD posted revenues of $4.22 billion compared to $2.97 billion in the year-ago quarter, beating analysts' average estimate of $4.12 billion.

BD's Medical segment was up 20 percent to $2.17 billion from $1.82 billion a year ago. BD Life Sciences revenues rose 12percent to $1.10 billion from $982 million in the prior-year quarter. Within the segment, preanalytical systems revenues rose 5 percent to $381 million from $363 million, while diagnostic systems revenues rose 17 percent to $410 million from $350 million, and biosciences revenues increased 14 percent to $307 million from $269 million.

Growth in the US Life Sciences segment was attributed to strength in the diagnostic systems and biosciences units, while revenues in the preanalytical systems unit were negatively impacted by a production issue in one of its product lines that was resolved in the quarter.  Life Science growth in the US was also aided by flu-related revenues in the diagnostic systems unit resulting from a strong fluseason. 

"Our results this quarter mark a significant milestone in our 120-year history, as we welcomed CR Bard to BD," Vincent Forlenza, BD chairman and CEO, said in a statement. BD completed the acquisition of Bard for $24 billion in late2017 after the two firms divested certain medical device product lines as requiredby the US Federal Trade Commission.

BD currently has approximately 30,000 Veritor immunoassay systems placed, said Alberto Mas, the firm's executive vice president and president of the life science segment. Mas noted that the firm is taking shares primarily from the manual testing space with Veritor." We launched our connected version of Veritor recently as well, which has enabled us to penetrate more on the retail segment," he said, adding that, in terms of broader menu, BD is working on additional assays for the system but that it is too early in the process to provide more detail. 

Revenues from the company's US business were up 43 percent to $2.33 billion from $1.63 billion a year ago, while revenues from international markets rose 41 percent to $1.90 billion from $1.34 billion in Q2 2017.

Internationally, revenues outside the US grew about 8 percent on a comparable, currency-neutral basis, the firm said, reflecting strong performance across the Medical, Life Sciences, and Interventional segments.

BD's net loss for the quarter was $12million, or $0.19 per share, compared to net income of $344 million, or $1.58 per share, a year ago. Adjusted EPS for the recently completed quarter was $2.65, beating the consensus Wall Street estimate of $2.63.

BD's R&D expenses rose 23 percent to $230 million from $187 million for Q2 2017, and its SG&A costs jumped 46 percent to $1.06 billion from $724 million. The costs for products sold also increased, 70 percent year over year to $2.62 billion from $1.54 billion, while costs associated with acquisitions and other restructurings rose 37 percent to $104 million from $76 million.

The company increased its full fiscal year 2018 revenue and adjusted earnings per share guidance. It now expects 31 to 31.5 percent revenue growth compared to a previous estimate of 30 to 31 percent growth. On a comparable, currency-neutral basis, the company raised its revenue guidance to 5. to 5.5 percent growth, which it said is the high end of its previous guidance range.

BD shares were down 3 percent to $223.10 inmorning trading on the New York Stock Exchange.